Neurocrine Biosciences, Inc. (NBIX)

Over the past six months, Neurocrine Biosciences' stock price has experienced several notable events. As of January 9, 2026, the stock traded at $135.79, decreasing by 12.25% in the past month. The 52-week high for NBIX was $160.18, reached on December 7, 2025, and the 52-week low was $84.23 on April 8, 2025. Neurocrine Biosciences released its Q3 2025 earnings, reporting an EPS of $2.17, surpassing estimates, and quarterly revenue increased by 27.8% year-over-year. The company provided an update on its Phase 3 study of valbenazine in dyskinetic cerebral palsy, which failed to meet its main goal. An insider, Darin Lippoldt, sold 4,376 shares of Neurocrine Biosciences stock. Morgan Stanley issued an "Equal Weight" rating on the stock, JPMorgan lowered its price target to $177 from $179 but maintained an Overweight rating, and RBC Capital and Needham & Company LLC adjusted their price targets and ratings.

Neurocrine Biosciences' Q3 2025 earnings call indicated that patient demand for CRENESSITY modestly favored the pediatric population versus adults and skewed towards female patients. Strong persistence and adherence rates give confidence in continued volume growth. This suggests some variability in demand, but no strong, overarching seasonality was explicitly stated for its major products across all markets.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, operating within the Health Care sector, specifically in the Biotechnology: Biological Products industry. The company's portfolio includes FDA-approved treatments such as INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, ALKINDI for adrenal insufficiency, EFMODY capsules for classic congenital adrenal hyperplasia, Orilissa tablets for endometriosis, and Oriahnn capsules for uterine fibroids. INGREZZA is also marketed as DYSVAL and REMLEAS in Japan. The company has a pipeline with compounds in mid-to late-phase clinical development across its core therapeutic areas.

Neurocrine Biosciences is headquartered in San Diego, California, U.S. The company discovers, develops, and markets pharmaceuticals in the United States and internationally. Its products are traded on various stock exchanges globally, including NASDAQ-GS (US), Munich Stock Exchange (Germany), Stuttgart Stock Exchange (Germany), Frankfurt Stock Exchange (Germany), Dusseldorf Stock Exchange (Germany), London Stock Exchange (UK), Berne Stock Exchange (Switzerland), Sao Paulo Stock Exchange (Brazil), and Milan Stock Exchange (Italy).

In the past year, Neurocrine Biosciences has maintained a strong reputation, reflected in its recognition on several Forbes lists for 2025 and 2026, including #30 Best Mid-Cap Companies (2026), #52 Most Trusted Companies in America (2025), and #194 America's Best Companies (2025) within the Drugs & Biotechnology industry. The company is considered a leading neuroscience-focused biopharmaceutical company. Analyst ratings generally indicate a "Moderate Buy" consensus. The Phase 3 study of valbenazine in dyskinetic cerebral palsy, which failed to meet its main goal, affected the company's reputation, but the company's overall reputation appears to remain strong due to its existing successful products and pipeline.

Institutional investors hold a significant portion of Neurocrine Biosciences' shares, ranging from 87.36% to 87.4% of the company. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Dodge & Cox, JPMorgan Chase & Co, and State Street Corp. Other notable institutional owners include Price T Rowe Associates Inc /Md/, Aqr Capital Management Llc, and Geode Capital Management, Llc. Individuals hold approximately 1.1% of the shares.